Journal
CASE REPORTS IN ONCOLOGY
Volume 10, Issue 2, Pages 683-688Publisher
KARGER
DOI: 10.1159/000479148
Keywords
Interstitial lung disease; Nanoparticle albumin-bound paclitaxel; Non-small cell lung cancer; Single-agent treatment
Categories
Funding
- Grants-in-Aid for Scientific Research [15K08657] Funding Source: KAKEN
Ask authors/readers for more resources
Interstitial lung disease (ILD) is a serious and potentially fatal adverse event in lung cancer therapy. Nanoparticle albumin-bound paclitaxel (nab-PTX) is a novel, solvent-free formulation of paclitaxel (PTX). Although the incidence of nab-PTX-induced ILD is not clear, it is generally considered that this formulation presents a similar risk of developing ILD as PTX. Here, we report 3 patients who developed severe ILD following treatment with nab-PTX. We draw attention to the risk of developing drug-induced ILD following nab-PTX treatment, and highlight that this novel formulation might therefore not be as safe as PTX with respect to the development of ILD. (C) 2017 The Author(s) Published by S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available